A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Susumu Takeuchi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
In recent years, as the availability of precision therapies expands, there is increasing reliance on genomic profiling assays to help identify the most appropriate treatment options for patients with advanced cancers. We retrospectively investigated the results of comprehensive genomic profiling tests from the time insurance coverage began until recently and examined the status of genetic analysis.
Methods
We retrospectively reviewed the analysis results of 300 patients with advanced solid tumors who consented to comprehensive genomic profiling tests from October 2019 to December 2022.
Results
Of the 300 patients who underwent comprehensive genomic profiling tests, analysis results for 274 patients were obtained, and were reviewed by the Clinical Genome Expert Panel. Six specimens (2%) were discontinued due to patient deaths and deteriorations in general condition. The three most frequently occurring actionable genomic alterations observed were TP53 (47.4%), KRAS (28.1%) and CDKN2A (20.4%). The most common druggable variant was CDKN2A, which was noted in 52 (19%) of 274 patients. The next most common were PIK3CA, BRAF, KRAS and PTEN. The cancer types that showed a greater median number of actionable alterations comprised thyroid cancer, pancreatic cancer and colorectal cancer.
Conclusions
In conclusion, comprehensive genomic profiling tests have the potential to be valuable in identifying genomic abnormalities. Even if there is no effective treatment at present, it may lead to a treatment in the future. Comprehensive genomic profiling tests should be considered for any cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Tokyo Medical University, Tokyo, Japan.
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
- Department of Clinical Oncology, Tokyo Medical University Hospital, Tokyo, Japan.
- Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
- Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
- Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
ORCID-Profile: Susumu Takeuchi
Zitieren
APA
Takeuchi, S., Yoshimura, A., Sofuni, A., Ueda, Y., Umezu, T., Kuroda, M., Sukeda, A., Matsubayashi, J., Nagao, T., Bingo, M., Inagaki, N., Ohira, T., Seike, M., & Ikeda, N. (2024). A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae128
Vancouver
Takeuchi S, Yoshimura A, Sofuni A, Ueda Y, Umezu T, Kuroda M, et al. A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae128
BibTeX
@article{Takeuchi2024,
author = {Takeuchi, Susumu and Yoshimura, Akinobu and Sofuni, Atsushi and Ueda, Yuri and Umezu, Tomohiro and Kuroda, Masahiko and Sukeda, Aoi and Matsubayashi, Jun and Nagao, Toshitaka and Bingo, Masato and Inagaki, Natsuko and Ohira, Tatsuo and Seike, Masahiro and Ikeda, Norihiko},
title = {A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae128}
}
EUVIMED